Acute Myeloid Leukemia with Persistent Marrow Aplasia after Chemotherapy Treated with Reduced-Intensity Allogeneic Stem Cell Transplantation.
- Author:
Hyunhwa YOON
1
;
Junshik HONG
;
Suyoung KIM
;
Dongmin LEE
;
Jinny PARK
;
Jeong Yeal AHN
;
Jae Hoon LEE
Author Information
1. Department of Internal Medicine, Gachon University School of Medicine, Incheon, Korea. alertjun@hanmail.net
- Publication Type:Case Report
- Keywords:
Acute myeloid leukemia;
Stem cell transplantation;
Aplastic anemia;
Neutropenia;
Chemotherapy
- MeSH:
Anemia, Aplastic;
Bone Marrow*;
Drug Therapy*;
Hematologic Diseases;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute*;
Mortality;
Neutropenia;
Sepsis;
Stem Cell Transplantation*;
Stem Cells*
- From:Korean Journal of Medicine
2014;86(2):242-246
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Persistent bone marrow aplasia after intensive chemotherapy is uncommon, but is one of the fatal complications in patients with acute myeloid leukemia (AML). Although allogeneic hematopoietic stem cell transplantation (HSCT) is considered to be contraindicated for patients who have hematologic diseases with serious infections, such as bacterial septicemia or invasive fungal diseases, combined with prolonged neutropenia due to frequent morbidity and mortality, such risks can be overcome by non-myeloablative conditioning and best supportive care. Here, we report an AML patient with persistent marrow aplasia after induction therapy, treated successfully with reduced-intensity allogeneic HSCT despite severe bacterial and fungal infections.
